XML 67 R61.htm IDEA: XBRL DOCUMENT v3.25.3
Legal Settlements and Loss Contingencies - Additional Information (Detail)
€ in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Nov. 30, 2020
EUR (€)
Loss Contingencies [Line Items]            
Legal settlements and loss contingencies, expenses $ 60 $ 450 $ 312 $ 638    
Accrued amount for legal settlements and loss contingencies $ 4,668   $ 4,668   $ 4,881 € 60.5
Opioid Litigation [Member] | United States [Member]            
Loss Contingencies [Line Items]            
Restructuring expense and income Expenses in the third quarter of 2025 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). Expenses in the third quarter of 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONE®, and an update to the estimated settlement provision for the opioid cases (mainly related to the settlement agreement with the city of Baltimore and the effect of the passage of time on the net present value of the discounted payments).   Expenses in the first nine months of 2025 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the United States in the generic drug antitrust litigation, as well as a provision recorded in connection with the antitrust litigation related to QVAR.